Latest Breaking News On - Specialty therapeutic - Page 1 : comparemela.com

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Hong kongNew zealandRepublic ofUnited statesHarald reinhartMatt ronsheimAcinetobacter baumanniiCenters for diseaseHead of global developmentZai lab limitedZai labSecurities exchangeInnoviva incDrug administrationZai lab forwardExchange commission

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaComunidad autonoma de catalunaUnited kingdomSarah mcleodDavid pattiAlison luckeyDennis riedlGabrielle kornmanDavid altaracHealth emergency preparednessGlobal antibiotic research development partnershipInnoviva incFoundation in genevaUs centers for diseaseInnoviva specialty therapeutics incInfectious disease global congress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to T

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resi.

South africaUnited kingdomUnited statesGrand duchy of luxembourgManica balasegaramDavid pattiPavel raifeldGlobal antibiotic research development partnershipLeo model foundationCorporate communicationsAfrican medical research councilUs national institute of allergyEntasis therapeutics incPublic health agency of canadaDrug administrationWorld health organization

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of.

South africaUnited kingdomUnited statesGrand duchy of luxembourgManica balasegaramPavel raifeldEntasis therapeuticsDrug administrationWorld health organizationUniversity of alabamaPublic health agency of canadaLeo model foundationJolla pharmaceutical companyUs national institute of allergyAfrican medical research councilGlobal antibiotic research development partnership

Innoviva Specialty Therapeutics: Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Specialty Therapeutics: Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaUnited statesUnited kingdomGrand duchy of luxembourgManica balasegaramDavid pattiPavel raifeldInnoviva incPublic health agency of canadaUniversity of alabamaEntasis therapeuticsJolla pharmaceutical companyDrug administrationAfrican medical research councilLeo model foundationUs national institute of allergy